Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells

Endocrinology

Volumn 144, Issue 7, 2003, Pages 2822-2828

  Graziani, Grazia ^a   Tentori, Lucio ^a   Portarena, Ilaria ^a   Vergati, Matteo ^a   Navarra, Pierluigi ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE; VALPROIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; ENDOMETRIUM CARCINOMA; ENZYME INHIBITION; EPILEPSY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TRANSCRIPTION TERMINATION;

ADENOCARCINOMA; CELL DIVISION; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; HUMANS; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 0038675351     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-0180     Document Type: Article

References (54)

1. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P 2001 Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci 943:296-315
2. Cohen CJ, Thomas GM, Hagopian GS 2000 Endometrial cancer. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei III E, eds. Cancer medicine. Hamilton-London: BC Decker Inc.; 1667-1682
3. MacGregor JI, Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196
4. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE 1995 Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279-2283
5. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE 2001 Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 61:7025-7029
6. Cheung E, Zarifyan AS, Kraus WL 2002 Histone H1 represses estrogen receptor α transcriptional activity by selectively inhibiting receptor-mediated transcription initiation. Mol Cell Biol 22:2463-2471
7. Pazin MJ, Kadonaga JT 1997 What's up and down with histone deacetylation and transcription? Cell 89:325-328
8. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE 2000 Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60:6890-6894
9. DeFazio A, Chiew YE, Donoghue C, Lee CS, Sutherland RL 1992 Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J Biol Chem 267:18008-18012
10. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
11. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
12. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV 1993 Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329:1383-1388
13. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV 1996 Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39:579-584
14. Isojarvi JI, Tauboll E, Pakarinen AJ, van Parys J, Rattya J, Harbo HF, Dale PO, Fauser BC, Gjerstad L, Koivunen R, Knip M, Tapanainen JS 2001 Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 111:290-296
15. Isojarvi JI, Tauboll E, Tapanainen JS, Pakarinen AJ, Laatikainen TJ, Knip M, Myllyla VV 2001 On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 42:305-310
16. TaubLll E, Isojarvi JI, Harbo HF, Pakarinen AJ, Gjerstad L 1999 Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure 8:490-493
17. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K 1985 Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynecol Jpn 37:1103-1111
18. Gravanis A, Gurpide E 1986 Effects of estradiol on deoxyribonucleic acid polymerase α activity in the Ishikawa human endometrial adenocarcinoma cell line. J Clin Endocrinol Metab 63:356-359
19. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, Navarra P 2002 CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143:807-813
20. Ponglikitmongkol M, Green S, Chambon P 1988 Genomic organization of the human oestrogen receptor gene. EMBO J 7:3385-3388
21. Tentori L, Portarena I, Bonmassar E, Graziani G 2001 Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating minor cells. Cell Death Differ 8:457-469
22. Boffa LC, Vidali G, Mann RS, Allfrey VG 1978 Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253:3364-3366
23. Barsalou A, Dayan G, Anghel SI, Alaoui-Jamali M, Van de Velde P, Mader S 2002 Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells. Mol Cell Endocrinol 190:65-73
24. McNamara JO 1996 Drugs effective in the therapy of epilepsies. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman GA, eds. Goodman, Gilman's the pharmacological basis of therapeutics. 9th ed (international edition). McGraw-Hill International; 476-477
25. O'Donnell T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH 2000 Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 880:84-91
26. Williams RS, Cheng L, Mudge AW, Harwood AJ 2002 A common mechanism of action for three mood-stabilizing drugs. Nature 417:292-295
27. Ruh MF, Tian S, Cox LK, Ruh TS 1999 The effects of histone acetylation on estrogen responsiveness in MCF-7 cells. Endocrine 11:157-164
28. Gray SG, Ekstrom TJ 2001 The human histone deacetylase family. Exp Cell Res 262:75-83
29. Zhou X, Marks PA, Rifkind RA, Richon VM 2001 Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA 98:10572-10577
30. Gao L, Cueto MA, Asselbergs F, Atadja P 2002 Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277:25748-25755
31. Zhou X, Richon VM, Rifkind RA, Marks PA 2000 Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc Natl Acad Sci USA 97:1056-1061
32. Kao HY, Downes M, Ordentlich P, Evans RM 2000 Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev 14:55-66
33. Lemercier C, Verdel A, Galloo B, Curtet S, Brocard MP, Khochbin S 2000 mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. J Biol Chem 275:15594-15599
34. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E 2002 Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9:45-57
35. Inokoshi J, Katagiri M, Arima S, Tanaka H, Hayashi M, Kim YB, Furumai R, Yoshida M, Horinouchi S, Omura S 1999 Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem Biophys Res Commun 256:372-376
36. Saunders N, Dicker A, Popa C, Jones S, Dahler A 1999 Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 59:399-404
37. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI 1999 Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res 59:2981-2988
38. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D 1999 Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274:34940-34947
39. Minucci S, Nervi C, Lo Coco F, Pelicci PG 2001 Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20:3110-3115
40. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA, Marks PA, Richon VM, Pandolfi PP 2001 Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321-1330
41. Pandolfi PP 2001 Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 48(Suppl 1):S17-S19
42. Kramer OH, Gottlicher M, Heinzel T 2001 Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294-300
43. Richon VM, O'Brien JP 2002 Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8:662-664
44. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE 2002 Phase I trial of the hlstone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728
45. Melnick A, Licht JD 2002 Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 9:322-332
46. Vigushin DM, Coombes RC 2002 Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13
47. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK 2001 Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202
48. Tittle TV, Schaumann BA 1992 Effect of antiepileptic drugs on growth of murine lymphoid tumor cells in single-cell culture. Epilepsia 33:729-735
49. Kawagoe R, Kawagoe H, Sano K 2002 Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26:495-502
50. Cinatl Jr J, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B 1996 Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7:766-773
51. Cinatl Jr J, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, Schwabe D 1997 Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8:958-963
52. Cinatl Jr J, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J 2002 Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-α. Jnt J Oncol 20:97-106
53. Driever PH, Knupfer MM, Cinatl J, Wolff JE 1999 Valproic acid for the treatment of pediatric malignant glioma. Klin Paediatr 211:323-328
54. Li R, El-Mallahk RS 2000 A novel evidence of different mechanisms of lithium and valproate neuroprotective action on human SY5Y neuroblastoma cells: caspase-3 dependency. Neurosci Lett 294:147-150